Full Press Release Details
LOS ANGELES--(BUSINESS WIRE)-- Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference , taking place from September 14 to 17, 2026, in Gstaad, Switzerland.
Niagen Bioscience CEO, Rob Fried, will participate in the Longevity Goes Mainstream: The Investment Case for Consumer Health Panel on Wednesday, September 16, from 14:50 - 15:30 p.m. CEST. Additionally, Mr. Fried and Niagen Bioscience Chief Financial Officer & Head of Business Development, Ozan Pamir, will attend one-on-one meetings with investors in person throughout the conference. Attendees will also have the opportunity to sample Tru Niagen ® on-site and experience Niagen™ Plus.
This year’s event will feature institutional investors, family offices, funds, and private investors with the world’s leading longevity scientists and key opinion leaders hosting panel discussions to create a forum aimed at amplifying breakthrough research and scientific advancement shaping the future of the longevity space.
If you would like to schedule a one-on-one meeting with the Niagen Bioscience management team during the conference, please contact your respective conference representative or email Niagen@KCSA.com .
For additional information on Niagen Bioscience, visit www.niagenbioscience.com .
About Niagen Bioscience
Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience ™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.
The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.
Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.
At the heart of its clinically tested product portfolio is Niagen ® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen ® , the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com ), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( www.niagenplus.com ). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.
Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com , where copies of press releases, news, and financial information are regularly published.
† Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)